Opis działalności
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
Zarząd & Rada nadzorcza
CEO |
Ugur Sahin |
Zarząd |
Jens Holstein, Özlem Türeci, Ryan Richardson, Sean Marett, Sierk Poetting |
Rada nadzorcza |
Helmut Jeggle, Michael Motschmann, Prof. Christoph Huber, Ulrich Wandschneider |
Dane firmy
Nazwa: |
BioNTech SE |
Adres: |
An der Goldgrube 12,DE-55131 Mainz |
Telefon: |
+49-6131-9084-0 |
Fax: |
+49-6131-9084-390 |
E-mail: |
info@biontech.de
|
Internet: |
https://biontech.de/de |
Przemysł: |
Biotechnologia |
Sektor: |
Biotechnologia |
Podsektor: |
Biotechnologia |
Koniec roku finansowego: |
31.12 |
Free float: |
- |
Data IPO: |
- |